Cyxone AB (publ) (CYXO.ST)
SEK 0.02
(0.0%)
SEK 0.02
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 43.65 Million SEK | -16.89% |
| 2022 | 52.52 Million SEK | 13.87% |
| 2021 | 46.12 Million SEK | -36.07% |
| 2020 | 72.15 Million SEK | -3.94% |
| 2019 | 75.11 Million SEK | -0.73% |
| 2018 | 75.67 Million SEK | 84.27% |
| 2017 | 41.06 Million SEK | 74.28% |
| 2016 | 23.56 Million SEK | 3480.85% |
| 2015 | 658 Thousand SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 38.54 Million SEK | -11.71% |
| 2024 Q2 | 33.01 Million SEK | -14.35% |
| 2023 Q1 | 47.13 Million SEK | -10.27% |
| 2023 FY | 43.65 Million SEK | -16.89% |
| 2023 Q4 | 43.65 Million SEK | 20.96% |
| 2023 Q3 | 36.09 Million SEK | 2.73% |
| 2023 Q2 | 35.13 Million SEK | -25.46% |
| 2022 Q1 | 84.98 Million SEK | 84.24% |
| 2022 Q2 | 65.92 Million SEK | -22.43% |
| 2022 Q3 | 56.78 Million SEK | -13.86% |
| 2022 Q4 | 52.52 Million SEK | -7.5% |
| 2022 FY | 52.52 Million SEK | 13.87% |
| 2021 FY | 46.12 Million SEK | -36.07% |
| 2021 Q1 | 62.48 Million SEK | -13.4% |
| 2021 Q3 | 58.56 Million SEK | -15.41% |
| 2021 Q2 | 69.24 Million SEK | 10.82% |
| 2021 Q4 | 46.12 Million SEK | -21.24% |
| 2020 Q2 | 53.63 Million SEK | -17.44% |
| 2020 Q1 | 64.96 Million SEK | -13.51% |
| 2020 Q4 | 72.15 Million SEK | 26.37% |
| 2020 FY | 72.15 Million SEK | -3.94% |
| 2020 Q3 | 57.09 Million SEK | 6.45% |
| 2019 FY | 75.11 Million SEK | -0.73% |
| 2019 Q4 | 75.11 Million SEK | 25.06% |
| 2019 Q3 | 60.06 Million SEK | -7.74% |
| 2019 Q2 | 65.1 Million SEK | -5.05% |
| 2019 Q1 | 68.56 Million SEK | -9.39% |
| 2018 Q2 | 32.99 Million SEK | -13.08% |
| 2018 Q1 | 37.95 Million SEK | -7.57% |
| 2018 FY | 75.67 Million SEK | 84.27% |
| 2018 Q4 | 75.67 Million SEK | 76.28% |
| 2018 Q3 | 42.92 Million SEK | 30.11% |
| 2017 FY | 41.06 Million SEK | 74.28% |
| 2017 Q1 | 33.36 Million SEK | 41.58% |
| 2017 Q2 | 31.68 Million SEK | -5.03% |
| 2017 Q3 | 30.1 Million SEK | -4.99% |
| 2017 Q4 | 41.06 Million SEK | 36.42% |
| 2016 Q2 | 25.8 Million SEK | 0.0% |
| 2016 FY | 23.56 Million SEK | 3480.85% |
| 2016 Q3 | 24.7 Million SEK | -4.24% |
| 2016 Q4 | 23.56 Million SEK | -4.64% |
| 2015 FY | 658 Thousand SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 63.145% |
| Ziccum AB (publ) | 14.97 Million SEK | -191.578% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -117.828% |
| BioArctic AB (publ) | 1.18 Billion SEK | 96.319% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 30.014% |
| Mendus AB (publ) | 755.95 Million SEK | 94.225% |
| Genovis AB (publ.) | 288.85 Million SEK | 84.887% |
| Intervacc AB (publ) | 259.61 Million SEK | 83.184% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -4.042% |
| Active Biotech AB (publ) | 44 Million SEK | 0.784% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 84.339% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 29.761% |
| Aptahem AB (publ) | 63.02 Million SEK | 30.734% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 91.203% |
| Kancera AB (publ) | 65.64 Million SEK | 33.496% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 87.575% |
| Fluicell AB (publ) | 9.34 Million SEK | -367.398% |
| Saniona AB (publ) | 64.14 Million SEK | 31.941% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -29.918% |
| Biovica International AB (publ) | 131.4 Million SEK | 66.779% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 17.609% |
| AcouSort AB (publ) | 34.51 Million SEK | -26.489% |
| Xintela AB (publ) | 18.39 Million SEK | -137.32% |
| Abliva AB (publ) | 87.49 Million SEK | 50.108% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 94.257% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 96.531% |
| OncoZenge AB (publ) | 20.34 Million SEK | -114.626% |
| Amniotics AB (publ) | 26.08 Million SEK | -67.35% |
| 2cureX AB (publ) | 16.62 Million SEK | -162.586% |
| CombiGene AB (publ) | 120.61 Million SEK | 63.805% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -618.364% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 97.703% |
| Camurus AB (publ) | 1.9 Billion SEK | 97.712% |
| Corline Biomedical AB | 100.1 Million SEK | 56.391% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 75.353% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 68.95% |
| I-Tech AB | 152.44 Million SEK | 71.363% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 95.712% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 44.524% |
| Biosergen AB | 7.2 Million SEK | -506.235% |
| Cantargia AB (publ) | 223.71 Million SEK | 80.486% |
| NextCell Pharma AB | 81.28 Million SEK | 46.296% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 94.295% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -44.682% |
| Nanologica AB (publ) | 77.42 Million SEK | 43.619% |
| SynAct Pharma AB | 228.01 Million SEK | 80.855% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -63.117% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -101.148% |
| LIDDS AB (publ) | 17.65 Million SEK | -147.267% |
| Lipum AB (publ) | 12.11 Million SEK | -260.487% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 96.882% |
| Alzinova AB (publ) | 123.18 Million SEK | 64.563% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 81.687% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -416.322% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 48.778% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -193.597% |
| Simris Alg AB (publ) | 174.55 Million SEK | 74.99% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 79.886% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 93.32% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 49.863% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -53.132% |